Studies of liver cancer models have shown that tyrosine kinase inhibitor (TKI) treatment induces the release of VEGF-enriched exosomes that in turn stimulate angiogenesis [89], and that EVs can also enable evasion from TKI-induced cell death by activating VEGF-independent pathways such those mediated by HGF [90]. The gene discussed is VEGFA; the disease is liver cancer.